Skip to content

US · ENGNW · BIOTECHNOLOGY

enGene Holdings Inc. Warrants (ENGNW) intrinsic value and stock valuation

$2.60as of 2026-09-18 · Mkt cap 10.24M

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

enGene Holdings Inc. Warrants DCF and intrinsic value

InvestorsCraft values ENGNW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ENGNW’s statements →

enGene Holdings Inc. Warrants Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Montreal, QC, CA engene.com

How the business is doing

Fiscal 2025–2020, USD

Revenue
$0.00
20252020
Net income
-$-15.07T
20252020
Free cash flow
-$-13.25T
20252020
Total equity
$127.4T
20252021

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2020, USD
FYFYFYFYFY
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-123.17T-$-62.3T-$-26.06T-$-19.43T-$-15.87T
Net income-$-117.3T-$-55.14T-$-99.92T-$-24.46T-$-23.44T
EPSd-$-2.29M-$-1.24M-$-4.24M-$-1.55M-$-1.48M
Operating cash flow-$-99.24T-$-48.28T-$-24.74T-$-17.59T-$-15.98T
Capital expenditure-$-1.49T-$-925B-$-318B-$-153B-$-248B
Free cash flow-$-100.72T-$-49.21T-$-25.06T-$-17.75T-$-16.23T
Total assets$221.5T$311.2T$87T$132T$131.4T
Total debt$31.8T$25T$9.78T$32.1T$4.16T
Net debt-$-18.36T-$-147.98T-$-71.74T-$-314.15B-$-1.07T
Total equity$167.7T$272.6T$72.5T$127.4T$127.4T
Cash and short-term investments$193.8T$238.4T$81.6T$314.2B$1.07T
Income statement
FYFYFYFYFY
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$94.5T$38.3T$16.5T$15.5T$12.5T
Selling, general and administrative expenses$28.7T$24T$8.47T$3.26T$3.16T
Other expenses$0.00$0.00$1.13T$700B$253B
Operating expenses$123.2T$62.3T$26.1T$19.4T$15.9T
Cost and expenses$123.2T$62.3T$26.1T$19.4T$15.9T
Interest income$9.43T$10.4T$1.12T$129B$25B
Interest expense$2.99T$2.8T$4.95T$1.42T$5.02T
Depreciation and amortization$509B$323B$175B$238B$272B
Ebitda-$-113.8T-$-52.04T-$-94.77T-$-22.78T-$-18.15T
Operating income-$-123.17T-$-62.3T-$-26.06T-$-19.43T-$-15.87T
Total other income/expenses, net$5.86T$7.14T-$-73.84T-$-5.01T-$-7.57T
Income before tax-$-117.3T-$-55.16T-$-99.9T-$-24.44T-$-23.44T
Income tax expense$0.00-$-19B$17B$22B$0.00
Net income-$-117.3T-$-55.14T-$-99.92T-$-24.46T-$-23.44T
Weighted average shares outstanding$51.1T$44.6T$23.6T$15.8T$15.8T
Weighted average diluted shares outstanding$51.1T$44.6T$23.6T$15.8T$15.8T
Balance sheet
FYFYFYFYFY
Cash and short-term investments$193.8T$238.4T$81.6T$314.2B$1.07T
Net receivables$2.23T$1.03T$2.34T$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$201.4T$247.4T$85.4T$511.8B$1.57T
Property, plant and equipment, net$10.2T$2.91T$589B$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$8.52T$59.5T$70B$131.5T$129.7T
Total non-current assets$20.1T$63.8T$1.52T$131.5T$129.9T
Total assets$221.5T$311.2T$87T$132T$131.4T
Accounts payable$6.69T$1.41T$1.16T$0.00$0.00
Short-term debt$10T$1.12T$562B$1.27T$1.05T
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$32T$14.7T$5.26T$893.5B$327.4B
Long-term debt$21.8T$23.9T$9.22T$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$3.73T
Total non-current liabilities$21.8T$23.9T$9.22T$3.73T$3.73T
Capital lease obligations$6.46T$1.43T$0.00$0.00$0.00
Total liabilities$53.8T$38.6T$14.5T$4.62T$4.05T
Common stock$513.3T$509.8T$259.4T$131.5T$129.7T
Retained earnings-$-372.03T-$-254.73T-$-199.59T-$-4.11T-$-2.28T
Accumulated other comprehensive income (loss)-$-888B-$-1.42T-$-1.02T$0.00$0.00
Total equity$167.7T$272.6T$72.5T$127.4T$127.4T
Total investments$152.2T$124.9T$146B$131.5T$129.7T
Total debt$31.8T$25T$9.78T$32.1T$4.16T
Net debt-$-18.36T-$-147.98T-$-71.74T-$-314.15B-$-1.07T
Cash flow statement
FYFYFYFYFY
Net income-$-117.3T-$-55.14T-$-99.92T-$-24.46T-$-23.44T
Depreciation and amortization$509B$323B$175B$238B$272B
Stock-based compensation$9.65T$5.32T$3.45T$116B$435B
Change in working capital$9.74T$95B-$-517B$2.17T-$-1.04T
Accounts receivable-$-595B$2.01T-$-1.01T$143B$295B
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$4.94T$474B$373B-$-197B$110B
Net cash provided by operating activities-$-99.24T-$-48.28T-$-24.74T-$-17.59T-$-15.98T
Investments in property, plant and equipment-$-1.49T-$-925B-$-318B-$-153B-$-248B
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-25.14T-$-125.95T-$-318B-$-153B-$-247B
Common stock issued$2.22T$260.1T$56.9T$12B$14B
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.52T$265.7T$86.1T$28T$22.5T
Net change in cash-$-122.85T$91.5T$61.1T$9.42T$6.39T
Cash at end of period$50.2T$173T$81.5T$20.4T$11T
Operating cash flow-$-99.24T-$-48.28T-$-24.74T-$-17.59T-$-15.98T
Capital expenditure-$-1.49T-$-925B-$-318B-$-153B-$-248B
Free cash flow-$-100.72T-$-49.21T-$-25.06T-$-17.75T-$-16.23T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About enGene Holdings Inc. Warrants

        EnGene Holdings Inc., through its enGene, Inc. subsidiary, is a clinical-stage biotechnology company dedicated to advancing genetic medicines. These innovative therapies are designed for targeted delivery to mucosal tissues and other bodily organs. Its foremost developmental asset, EG-70 (detalimogene voraplasmid), represents a non-viral immunotherapy. This treatment is specifically aimed at patients with non-muscle invasive bladder cancer, specifically the carcinoma-in-situ (CIS) subtype, who have shown no response to Bacillus Calmette-Guérin (BCG) therapy. Established in 2023, the firm's operations are based in Saint-Laurent, Canada.

        CEO
        Ronald H. W. Cooper
        Employees
        82
        Beta
        -0.28

        Explore

        Frequently asked questions

        What is the intrinsic value of enGene Holdings Inc. Warrants (ENGNW)?

        InvestorsCraft does not currently publish an intrinsic value for ENGNW. How the IC value is calculated.

        Is ENGNW undervalued?

        InvestorsCraft does not publish an undervaluation signal for ENGNW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.